Blood

Vol. 147, Issue 23 Issue 23 2026
24
Articles

Articles in this Issue

Patient-derived lymphoma spheroids reveal predictive markers of glofitamab resistance in relapsed/refractory B-NHL

Paul Marcoux, Fabien Gava, Marie Tosolini et al. Jun 04, 2026 pp. 2770-2785 10.1182/blood.2025031309

Abstract Bispecific antibodies (bsAbs) such as glofitamab represent a promising therapeutic approach for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), but resistance...

Another “one stone hit two birds” candidate in chronic GVHD

Daniel Wolff Jun 04, 2026 pp. 2711-2712 10.1182/blood.2026033671

Clonal tracing of blood stem cells across mouse and human lifespans

Alejo E. Rodriguez-Fraticelli Jun 04, 2026 pp. 2728-2739 10.1182/blood.2024028195

Abstract For over 60 years, blood researchers have been counting clones with every tool at their disposal. Inspired by phage and fly geneticists, Till and McCulloch irradiated mice...

CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation

Simone A. Minnie, Kenneth Ho, Julie R. Boiko et al. Jun 04, 2026 pp. 2786-2792 10.1182/blood.2025030207

Abstract Autologous stem cell transplantation (ASCT) with maintenance lenalidomide remains the mainstay of consolidation therapy for eligible patients with multiple myeloma, but pr...

Methylation-based lineage tracing in cancer

Jiaoyi Chen, Benson Z. Wu, Federico Gaiti Jun 04, 2026 pp. 2749-2759 10.1182/blood.2024028196

Abstract The evolutionary history of cancers is encoded in molecular patterns that provide critical insights into the mechanisms of tumor progression. However, reconstructing cance...

Homeodomain-driven oncogenic diversion to a γδTCR phenotype in T-cell acute lymphoblastic leukemia

Antoine Pinton, Lucien Courtois, Manon Delafoy et al. Jun 04, 2026 pp. 2793-2808 10.1182/blood.2025030626

Abstract T-cell acute lymphoblastic leukemia (T-ALL) results from the malignant transformation of thymocytes blocked in their differentiation. Surface expression of the γδ T-cell r...

The evolution of hematopoietic models through a clonal lens

Sara Tomei, Tom S. Weber, Shalin H. Naik Jun 04, 2026 pp. 2740-2748 10.1182/blood.2024028189

Abstract Hematopoiesis is a tightly regulated process through which a small pool of stem cells sustains the lifelong production of all blood cell types in response to physiological...

United forces bring down menin resistance in AML

Thorsten Braun Jun 04, 2026 pp. 2707-2709 10.1182/blood.2026033473

Kumskova M, Flora GD, Nayak MK, et al. Platelet defects in patients and mice with Ehlers-Danlos syndrome. <i>Blood</i> . 2026;147(9):987-997.

Jun 04, 2026 pp. 2846-2847 10.1182/blood.2026034273

The fibrinogen αC region promotes arterial thrombosis in the context of hypofibrinogenemia

Robert H. Lee, Francesca Ferraresso, Alexander Couzens et al. Jun 04, 2026 pp. 2821-2827 10.1182/blood.2025031456

Abstract Hypofibrinogenemia reduces experimental venous thrombosis, but the impact on arterial thrombosis remains unknown. In a cohort of patients with congenital fibrinogen disord...

Tipping the balance on lenalidomide maintenance

Tom Cupedo Jun 04, 2026 pp. 2705-2706 10.1182/blood.2026033617

Introduction to a review series on clonal tracking in hematopoiesis

Diane S. Krause Jun 04, 2026 pp. 2699-2699 10.1182/blood.2026034019

Over the past decade, advances in single-cell genomics, lineage tracing, and computational phylogenetics have transformed our understanding of hematopoiesis by enabling detailed reconstruction of hema...

Distinct effects of <i>CREBBP</i> missense and truncating mutations

Ralf Küppers Jun 04, 2026 pp. 2701-2702 10.1182/blood.2026033255

Predicting and reversing T-cell engager resistance

June Helen Myklebust Jun 04, 2026 pp. 2704-2705 10.1182/blood.2026033471

Measurable residual disease in myeloma: a MyRiaD of findings

Noemi Puig Jun 04, 2026 pp. 2702-2703 10.1182/blood.2025032857

T-ALL: the origin story

Piers Blombery Jun 04, 2026 pp. 2706-2707 10.1182/blood.2025032944

BET inhibition blunts antibody production and macrophage-mediated fibrosis to restore lung function in murine cGVHD

Rathan Kumar, Lotus Neidemire-Colley, Elizabeth A. R. Garfinkle et al. Jun 04, 2026 pp. 2828-2844 10.1182/blood.2025031983

Abstract Chronic graft-versus-host disease (cGVHD) significantly contributes to late mortality after allogeneic stem cell transplantation, with bronchiolitis obliterans syndrome (B...

Shrouded in a starry sky: a case of AML-MRC with <i>KMT2A</i> amplification mimicking Burkitt-like morphology

Radu Chiriac, Vincent Alcazer Jun 04, 2026 pp. 2845-2845 10.1182/blood.2026033109

Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor

Warren Fiskus, Christopher P. Mill, Ghayas C. Issa et al. Jun 04, 2026 pp. 2809-2820 10.1182/blood.2025031486

Abstract Menin inhibitors (MI) disrupt the binding of menin to mixed-lineage leukemia 1 (MLL1), leading to the repression of MLL1 or MLL1-fusion protein target genes, including red...

Differential role of <i>CREBBP</i> missense and truncating mutations in germinal center development and lymphomagenesis

Chuanjiang Yu, Mara Holloman, Andrew Kim et al. Jun 04, 2026 pp. 2713-2727 10.1182/blood.2025031181

Abstract Truncating and missense mutations of the CREBBP gene are highly prevalent in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), the most common lymphoid m...

Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study

Robert Z. Orlowski, Meletios A. Dimopoulos, Xavier Leleu et al. Jun 04, 2026 pp. 2760-2769 10.1182/blood.2025030120

Abstract Quadruplet therapy with Isa-VRd (isatuximab, Velcade [bortezomib], Revlimid [lenalidomide], and dexamethasone) followed by Isa-Rd in the randomized phase 3 IMROZ study pro...

Tadagaki K, Tudor D, Gbahou F, et al. Human cytomegalovirus-encoded UL33 and UL78 heteromerize with host CCR5 and CXCR4 impairing their HIV coreceptor activity. <i>Blood</i> . 2012;119(21):4908-4918.

Jun 04, 2026 pp. 2849-2849 10.1182/blood.2026034416

Fibrinogen wags its disordered tail: α chain and thrombosis

Cédric Duval Jun 04, 2026 pp. 2709-2711 10.1182/blood.2026033618

Wang Z, Skwarska A, Poigaialwar G, et al. Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of <i>JAK2</i> -mutated post-MPN AML. <i>Blood</i> . 2025;146(3):341-355.

Jun 04, 2026 pp. 2848-2848 10.1182/blood.2026034351

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page